Tislelizumab (TIS) + Chemotherapy (CT) Versus Placebo + CT as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: RATIONALE-305 European/North American Patient Subgroup

Filippo Pietrantonio,[1] Tobias Arkenau,[2] Josep Tabernero,[3] Marcia Cruz Correa,[4] Elena Poddubskaya,[5] Fedor Vladimirovich Moiseenko,[6] David Spigel,[7] Lucjan Wyrwicz,[8] Umut Disel,[9] Roberto Pazo Cid,[10] Antonio Cubillo Gracian,[11] Inmaculada Ales Diaz,[12] Lorenzo Fornaro,[13] Ludovic Evesque,[14] Yaling Xu,[15] Tao Sheng,[16] Silu Yang,[17] Liyun Li,[17]* Markus Moehler,[18] Rui Hua Xu[19]

[1]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; [2]Sarah Cannon Research Institute, London, UK; [3]Vall d'Hebron Hospital Campus, Barcelona, Spain; [4]University of Puerto Rico, San Juan, Puerto Rico; [5]Vitamed LLC, Moscow, Russia; [6]Saint Petersburg Clinical Scientific and Practical Centre, Saint Petersburg, Russia; [7]Tennessee Oncology PLLC, Nashville, TN, USA; [8]Narodowy Instytut Onkologii, Warsaw, Poland; [9]Acibadem Adana Hospital, Adana, Turkey; [10]Hospital Universitario Miguel Servet, Zaragoza, Spain; [11]Hospital Madrid Norte Sanchinarro, Madrid, Spain; [12]Hospital Regional Universitario de Malaga, Malaga, Spain; [13]Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; [14]Centre Antoine Lacassagne, Nice, France; [15]BeiGene (Shanghai) Co., Ltd., Shanghai, China; [16]BeiGene, Ltd., Boston, MA, USA; [17]BeiGene (Beijing) Co., Ltd., Beijing, China; [18]Johannes Gutenberg-University Clinic, Mainz, Germany; [19]Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
* Affiliation at the time of study

Poster No: A46 Presented at XXVI Italian Medical Oncology Association (AIOM); November 8–10, 2024; Rome, Italy

Conclusions

- **In the European/North American (Eu/NA) patient subgroup analysis of RATIONALE-305, tislelizumab (TIS) plus chemotherapy (CT) showed overall survival (OS) improvement in the intent-to-treat (ITT) analysis set and programmed death-ligand 1-positive (PD-L1+) analysis set compared with placebo (PBO) plus CT, as first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)**
- **OS improvement with TIS+CT in the Eu/NA patient subgroup was accompanied by favorable progression-free survival (PFS), objective response rate (ORR), and median duration of response (DoR). TIS+CT had a manageable safety profile. These results are consistent with previously published results in the overall study population**

Background

- GC is the fifth most common cancer globally.[1] The prognosis for patients with advanced unresectable or metastatic GC/GEJC treated with standard-of-care CT remains unsatisfactory,[2] but the addition of anti-programmed cell death protein-1 (PD-1) antibodies to CT has been shown to improve survival[3]
- TIS, an anti-PD-1 monoclonal antibody, plus CT, demonstrated significant OS benefit versus PBO+CT (hazard ratio [HR]=0.80, 95% confidence interval [CI]: 0.70, 0.92) as first-line therapy in patients with advanced GC/GEJC in the randomized, double-blind, global, phase 3 RATIONALE-305 study (NCT03777657)[4]
- Here, we present the efficacy and safety results from the Eu/NA patient subgroup analysis from the RATIONALE-305 study

Methods

- The design of the double-blind, global, phase 3 RATIONALE-305 study has been previously described[4]
- Eligible patients were randomized (1:1) to receive TIS 200 mg or placebo (PBO) intravenously once every 3 weeks plus investigator-chosen CT (5-fluorouracil + cisplatin or capecitabine + oxaliplatin)
- The primary endpoint was OS in both the ITT analysis set and the PD-L1+ analysis set (patients with tumor area positivity score ≥5%)
- Secondary endpoints included PFS, ORR, DoR, and safety

Results

Patient Baseline Characteristics

- A total of 997 patients were enrolled in the study, of whom 249 (25.0%) were included in the Eu/NA patient subgroup analysis (TIS+CT, n=125; PBO+CT, n=124)
- Patient baseline characteristics were generally balanced between treatment arms (**Table 1**)
- At data cutoff (February 28, 2023), minimum follow-up in the overall population was 24.6 months for TIS+CT and 25.0 months for PBO+CT

Table 1. Demographics and Baseline Disease Characteristics

	Eu/NA Patient Subgroup		
	TIS+CT (n=125)	PBO+CT (n=124)	Total (n=249)
Median age, years (range)	61.0 (23.0–83.0)	62.5 (30.0–86.0)	62.0 (23.0–86.0)
Sex, Male, n (%)	88 (70.4)	85 (68.5)	173 (69.5)
ECOG PS, n (%)			
0	49 (39.2)	52 (41.9)	101 (40.6)
1	76 (60.8)	72 (58.1)	148 (59.4)
Primary tumor location, n (%)			
Stomach	76 (60.8)	76 (61.3)	152 (61.0)
GEJ	49 (39.2)	48 (38.7)	97 (39.0)
Metastatic disease, n (%)	121 (96.8)	121 (97.6)	242 (97.2)
Peritoneal metastasis, n (%)	55 (44.0)	54 (43.5)	109 (43.8)
Prior adjuvant/neoadjuvant treatment, n (%)	23 (18.4)	17 (13.7)	40 (16.1)
PD-L1 score, n (%)			
<5%	53 (42.4)	53 (42.7)	106 (42.6)
≥5%	72 (57.6)	71 (57.3)	143 (57.4)

Data cutoff: February 28, 2023. [a]Disease stage rating at screening was based on American Joint Committee on Cancer TNM Staging Classification for Carcinoma of the Stomach and for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed., 2017).
CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; Eu/NA, European/North American; GEJ, gastroesophageal junction; ITT, intent-to-treat; PBO, placebo; PD-L1, programmed death-ligand 1; TIS, tislelizumab.

Efficacy

- In the Eu/NA subgroup, TIS+CT improved OS compared with PBO+CT in the ITT analysis set (HR=0.71, 95% CI: 0.54, 0.94) and PD-L1+ analysis set (HR=0.75, 95% CI: 0.52, 1.07) (the HR results for OS in this subgroup should be interpreted with caution) (**Figure 1**)
- OS rates at 24 months were higher with TIS+CT versus PBO+CT in the ITT analysis set (27.6% vs 13.6%) and PD-L1+ analysis set (27.6% vs 12.5%)
- TIS+CT resulted in favorable PFS, numerically higher ORR, and longer DoR versus PBO+CT (**Table 2**)

Figure 1. OS in the Eu/NA Patient Subgroup in the (A) ITT Analysis Set and (B) PD-L1+ Analysis Set

	TIS+CT (n=125)	PBO+CT (n=124)
Events	96	108
Median OS, months (95% CI)	11.0 (8.4, 13.9)	10.5 (8.1, 12.1)
HR (95% CI)	0.71 (0.54, 0.94)	



No. of Patients at Risk:

TIS+CT	125	114	99	88	73	64	54	49	42	42	37	35	32	27	21	13	5	5	5	1	1	0
PBO+CT	124	111	98	86	69	58	47	36	30	21	18	15	15	13	9	5	3	1	1	0	0	0

	TIS+CT (n=72)	PBO+CT (n=71)
Events	57	62
Median OS, months (95% CI)	10.2 (7.5, 15.0)	10.7 (7.9, 12.8)
HR (95% CI)	0.75 (0.52, 1.07)	



No. of Patients at Risk:

TIS+CT	72	67	59	52	43	35	30	28	26	26	23	21	19	16	12	7	3	3	3	0	
PBO+CT	71	66	59	50	41	35	29	23	18	12	9	8	8	8	4	3	2	1	1	0	

Data cutoff: February 28, 2023. Data are n (%).
CT, chemotherapy; PBO, placebo; TIS, tislelizumab; TRAE, treatment-related adverse event.

Table 2. Efficacy Endpoints (ITT Analysis Set)

	Eu/NA Patient Subgroup	
	TIS+CT (n=125)	PBO+CT (n=124)
Median PFS, months (95% CI)	5.6 (4.4, 7.0)	5.4 (4.3, 5.9)
HR	0.84 (0.63, 1.11)	
ORR,[a] % (95% CI)[b]	36.0 (27.6, 45.1)	31.5 (23.4, 40.4)
Median DoR,[a] months (95% CI)	7.5 (4.4, 12.0)	5.0 (3.9, 6.7)

Data cutoff: February 28, 2023. Medians were estimated by the Kaplan–Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley. [a]Among patients with a confirmed partial or complete response per RECIST version 1.1. [b]Exact Clopper–Pearson 2-sided CI.
Chemo, chemotherapy; CI, confidence interval; DoR, duration of response; Eu/NA, European/North American; HR, hazard ratio; ITT, intent-to-treat; ORR, objective response rate; PBO, placebo; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; TIS, tislelizumab.

Safety

- Incidences of grade ≥3 treatment-related adverse events (TRAEs) (48.8% vs 49.2%) and TRAEs leading to death (1.6% vs 0.8%) were similar between arms, while more patients discontinued treatment (13.0% vs 5.6%) due to TRAEs with TIS+CT versus PBO+CT, respectively
- Overall, the safety profile of TIS+CT was manageable in patients with locally advanced unresectable or metastatic GC/GEJC in the Eu/NA subgroup (**Table 3**)

Table 3. Safety Summary (Safety Analysis Set)

	Eu/NA Patient Subgroup	
	TIS+CT (n=125)	PBO+CT (n=124)
TRAE of any grade, n (%)	117 (95.1)	116 (93.5)
TRAE of grade ≥3, n (%)	60 (48.8)	61 (49.2)
TRAE leading to discontinuation,[a] n (%)	16 (13.0)	7 (5.6)
TRAE leading to death, n (%)	2 (1.6)	1 (0.8)

Data cutoff: February 28, 2023. [a]Discontinuation of any treatment component.
CT, chemotherapy; Eu/NA, European/North American; PBO, placebo; TIS, tislelizumab; TRAE, treatment-related treatment-emergent adverse event.

References

1. Globocan 2020. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed August 17, 2023.
2. Lordick F, et al. *Ann Oncol* 2022;33:1005-20.
3. Janjigian YY, et al. *Lancet*. 2021;398(10294):27-40.
4. Xu R, et al. *Ann Oncol*. 2023;34(suppl_2):S1320-S1321.

Acknowledgments

We would like to thank the investigators, site support staff, and especially the patients for participating in this study. This study was funded by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Saxony Olivier, MMed For Path (SA), of Ashfield MedComms, an Inizio company, and Steven Moore, PhD, and Smitha Reddy, PhD, of Envision Pharma Inc., and was funded by BeiGene.

Presenter Disclosures

Filippo Pietrantonio reports institutional research funding from Agenus, Amgen, AstraZeneca, BMS, Incyte, and Lilly; and speaker fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Daiichi-Sankyo, GSK, Ipsen, Johnson & Johnson, Merck-Serono, MSD, Pierre-Fabre, Rottapharm, Seagen/Pfizer, Servier, and Takeda.

Contact: Filippo.Pietrantonio@istitutotumori.mi.it (Filippo Pietrantonio)